Fig. 2.
Individual and geometric mean AUC0–t and Cmax of a caffeine, b omeprazole, and c midazolam alone versus each cocktail drug plus adavosertib, and d individual and geometric mean of adavosertib plus cocktail (part A) versus adavosertib alone (part B). *Individual patient and geometric mean AUC0–t and Cmax in the presence and absence of adavosertib 225 mg bid for caffeine (n = 25), omeprazole (n = 27), and midazolam (n = 23); †Adavosertib + cocktail: caffeine (200 mg tablet), omeprazole (20 mg capsule), and midazolam (1 mL of 2 mg/mL syrup formulation) on day 3 and adavosertib 225 mg (3 × 75 mg capsules) on day 3 (part A). Adavosertib: adavosertib 225 mg (3 × 75 mg capsules) bid on days 1 and 2 and once on day 3 (part B/pharmacodynamic study). AUC0–12 area under the plasma concentration–time curve from time zero to 12 h, AUC0–t area under the plasma concentration–time curve from time zero to time of the last quantifiable concentration, Cmax maximum plasma drug concentration